Financial Architects Inc Lifted Holding in Celgene Co. (CELG)

Financial Architects Inc Lifted Holding in Celgene Co. (CELG)

Financial Architects Inc raised its position in shares of Celgene Co. (NASDAQ:CELG) by 4.5% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 1,806 shares of the biopharmaceutical company’s stock after buying an additional 77 shares during the period. Financial Architects Inc’s holdings in Celgene were worth $225,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Motco boosted its stake in Celgene by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 620 shares in the last quarter. Barnett & Company Inc. boosted its stake in Celgene by 18.3% in the third quarter. Barnett & Company Inc. now owns 1,130 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 175 shares in the last quarter. Carroll Financial Associates Inc. boosted its stake in Celgene by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 400 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new stake in Celgene during the fourth quarter worth $146,000. Finally, Reilly Financial Advisors LLC boosted its stake in Celgene by 15.3% in the first quarter. Reilly Financial Advisors LLC now owns 1,211 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 161 shares in the last quarter. Institutional investors own 77.68% of the company’s stock.

Shares of Celgene Co. (NASDAQ:CELG) opened at 116.41 on Friday. The stock has a market cap of $90.90 billion, a price-to-earnings ratio of 43.71 and a beta of 1.74. The stock’s 50 day moving average price is $120.53 and its 200 day moving average price is $119.80. Celgene Co. has a 52 week low of $94.42 and a 52 week high of $127.64. Celgene also was the recipient of some unusual options trading activity on Wednesday. Investors purchased 1,866 call options on the stock. This is an increase of 197% compared to the average daily volume of 629 call options.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.21. Celgene had a net margin of 17.80% and a return on equity of 77.95%. The firm had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $3.04 billion. During the same period last year, the firm posted $1.32 EPS. The firm’s quarterly revenue was up 17.8% on a year-over-year basis. Equities research analysts anticipate that Celgene Co. will post $7.29 EPS for the current fiscal year.

A number of analysts have recently commented on the company. Mizuho lifted their target price on Celgene from $130.00 to $134.00 and gave the stock a “buy” rating in a research report on Thursday. BTIG Research reiterated a “buy” rating and set a $138.00 target price on shares of Celgene in a research report on Wednesday, May 24th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Celgene in a research report on Wednesday, May 24th. Cantor Fitzgerald set a $160.00 target price on Celgene and gave the stock a “buy” rating in a research report on Monday, May 22nd. Finally, Canaccord Genuity set a $156.00 target price on Celgene and gave the stock a “buy” rating in a research report on Monday, May 22nd. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. Celgene has an average rating of “Buy” and an average price target of $139.05.

In related news, Director James J. Loughlin sold 9,250 shares of Celgene stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $124.00, for a total transaction of $1,147,000.00. Following the completion of the transaction, the director now directly owns 32,169 shares of the company’s stock, valued at approximately $3,988,956. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gilla Kaplan sold 14,033 shares of Celgene stock in a transaction dated Thursday, March 30th. The shares were sold at an average price of $123.83, for a total transaction of $1,737,706.39. Following the transaction, the director now directly owns 73,109 shares of the company’s stock, valued at $9,053,087.47. The disclosure for this sale can be found here. Company insiders own 0.97% of the company’s stock.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CELG”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Related posts

Leave a Comment